AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03242772
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo tablets will be administered in the morning and provided for 11 weeks . The tablets will be titrated in the same way as the active drug and may be stopped at any time.
Trial: NCT01638208
Drug: VSL#3
RxNorm normalized name: VSL#3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage Form: Capsules (Details as given below); Dose and duration of treatment: 1 capsule b.i.d for 8 weeks; Each capsule contains 112.5 Billion CFU of the following 8 strains of bacteria, 4 lactobacilli strains (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp bulgaricus), 3 bifidobacteria strains (B. breve, B. infantis, B. longum) and 1 strain of S. thermophilus).
Trial: NCT02393846
Drug: Ketoprofen gel
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ketoprofen as used in gel form.
Trial: NCT02393846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel which is identical in colour, form and smell compared to ketoprofen gel.
Trial: NCT01015586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 12 weeks
Trial: NCT02759666
Drug: SHR3162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR3162 capsule(s) is administered orally QD.
Trial: NCT02788201
Drug: 75 approved agents
RxNorm normalized name: MISCELLANEOUS AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One or combination of agents: Abiraterone, Arsenic Trioxide, Asparaginase Escherichia coli source, Axitinib, Azacitidine, Bendamustine, Bleomycin, Bortezomib, Busulfan, Carboplatin, Carfilzomib, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Crizotinib, Cytarabine, Dacarbazine, Dactinomycin, Dasatinib, Daunorubicin, Decitabine, Docetaxel, Doxorubicin, Epirubicin, Eribulin, Erlotinib, Estramustine, Etoposide, Exemestane, Floxuridine, Fludarabine, Fluorouracil, Gefitinib, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Irinotecan, Ixabepilone, Lapatinib, Lomustine, Mechlor, Melphalan, Mercapto, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Nilotinib, Oxaliplatin, Paclitaxel, Pazopanib, Pentostatin, Romidepsin, Ruxolitinib, Sorafenib, Streptozocin, Sunitinib, Tamoxifen, Temsirolimus, Teniposide, Thioguanine, Thiotepa, Topotecan, Toremifene, Tretinoin, Vandetanib, Vemurafenib, Vinblastine, Vincristine, Vismodegib, and/or Vorinostat
Trial: NCT00977938
Drug: Placebo & Aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01561755
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 2gr/kg over 2 days of saline
Trial: NCT00622089
Drug: DIO-902
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg DIO-902 + 10mg atorvastatin
Trial: NCT00622089
Drug: DIO-902
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg dose once per day for 24 weeks
Trial: NCT00622089
Drug: DIO-902
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450mg dose once per day for 24 weeks
Trial: NCT01632228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
Trial: NCT02230761
Drug: XOPH5 Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02230761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00353431
Drug: Novorapid ®, Novo Nordisk, Denmark
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of a sliding scale with an intensive s.c. scale
Trial: NCT00113646
Drug: MEDI-507
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-507 0.1 mg/kg on transplant day-8, 0.6 mg/kg on days-7 and -6
Trial: NCT02363374
Drug: Induction Chemotherapy arm A
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive three induction chemotherapy cycles, starting on day 1, 15 and 29, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv~After a break of two weeks, radiotherapy starts combined with:~5-FU: 250 mg/sqm per day, iv, on day 43-57, day 64-77 Oxaliplatin: 50 mg/sqm, day 43, 50, 64, and 71
Trial: NCT02363374
Drug: Chemotherapy arm B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29.~After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv
Trial: NCT00033540
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 650 mg/m\^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days
Trial: NCT00263640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.
Trial: NCT02031081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 X 100mg tablets (encapsulated) by mouth once daily for 28 days
Trial: NCT03880448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cornstarch 500mg/8h/7days
Trial: NCT02086942
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,4 cycles. Intensive therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,5 cycles. Maintenance treatment with CP: 200mg PO Days 1-14 of each 28 day cycles,12 cycles.
Trial: NCT02466074
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm
Trial: NCT01028716
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00619346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, BID X 14 days
Trial: NCT01482897
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
Trial: NCT01482897
Drug: sham procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
Trial: NCT01482897
Drug: comparator : physiological solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
Trial: NCT04214652
Drug: IDP-126 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-126 Gel applied topically to the face once daily for 12 weeks.
Trial: NCT04214652
Drug: IDP-126 Vehicle Gel
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
Trial: NCT03778320
Drug: D-Serine
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT03958591
Drug: CSII and thereafter combination therapy, followed up with wearable devices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Wearable devices and smart apps will be used to manage and follow-up the participants.
Trial: NCT03958591
Drug: CSII and thereafter combination therapy, followed up in traditional ways
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Traditional ways such as telephone contact will be used for follow up.
Trial: NCT03958591
Drug: Traditionally upgrading therapy, followed up in traditional ways
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will be applied the combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks. Traditional ways will be used for follow up.
Trial: NCT00197145
Drug: GW873140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg twice daily
Trial: NCT04326036
Drug: Liberase Enzyme (Roche)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile Collagenase Blend to separate cSVF from the AD-SVF
Trial: NCT00743028
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
Trial: NCT00743028
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
Trial: NCT01760473
Drug: Intranasal challenge drug
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each of the experimental challenge drugs were administered intranasally to all participants in random order.
Trial: NCT00678535
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m\^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
Trial: NCT01537081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets in two formulations to match either Mucinex or IR guaifenesin taken by mouth with a full glass of water
Trial: NCT03452033
Drug: H-1337 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-1337 Placebo Vehicle
Trial: NCT03452033
Drug: H-1337 [1]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-1337 Ophthalmic Solution Concentration 1
Trial: NCT03452033
Drug: H-1337 [2]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-1337 Ophthalmic Solution Concentration 2
Trial: NCT03452033
Drug: H-1337 [3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-1337 Ophthalmic Solution Concentration 3
Trial: NCT01192503
Drug: placebo (sugar pill)
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg (2 tablets of 0.5mg) taken at bedtime by mouth for 12 weeks
Trial: NCT02937857
Drug: Standard treatment only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard treatment， such as antiasthmatic,expectorant,antipyretic
Trial: NCT02937857
Drug: Standard treatment+Xiyanping injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.
Trial: NCT00652184
Drug: ARYS-01 (sorivudine) cream 3% or placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorivudine cream 3% or placebo cream twice daily for 10 days
Trial: NCT00652184
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo cream and placebo valaciclovir
Trial: NCT03666351
Drug: Amlodipine/Losartan/Chlorthalidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg/Losartan Potassium 100 mg/Chlorthalidone 12.5 mg
Trial: NCT03666351
Drug: current treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment is done by maintaining the current treatment
Trial: NCT03404908
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
Trial: NCT00612742
Drug: testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily transdermal testosterone gel, 300 mcg
Trial: NCT00612742
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily transdermal placebo gel
Trial: NCT03283098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplied to match active intervention.
Trial: NCT03980821
Drug: AZD4635
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4635 taken orally
Trial: NCT03110653
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil will be continued postoperatively, while being decreased (gradually by 30% every 15 mins)
Trial: NCT03110653
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% will be administered postoperatively, while being decreased by 30% every 15 mins.
Trial: NCT02251717
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg FDC tablet administered orally once daily
Trial: NCT03780478
Drug: Nerve block
RxNorm normalized name: Nerve Block Tray 22g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine with epinephrine (1:100k), with total volume of 2mL
Trial: NCT03780478
Drug: Placebo Saline Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline injection, total volume 2ml
Trial: NCT02688088
Drug: Drug Cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01842932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for double-blind study These are harmless to the human body, and are composed of saline solution without drug efficacy.
Trial: NCT00002839
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01839019
Drug: Placebo for ODM-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose escalation
Trial: NCT00803348
Drug: Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls/hr until 0600 on postoperative day 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.2% ropivicaine at an infusion rate of 5mls/hr with patient controlled boluses of 5ml available every 30 mins, until 0600 on the morning of postoperative day 2
Trial: NCT00803348
Drug: Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls/hr until 0600 on post-operative day 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.1% ropivicaine at an infusion rate of 10mls/hr with patient controlled boluses of 10mls available every 30 mins, until 0600 on the morning of postoperative day 2
Trial: NCT05143723
Drug: Gonadotropin-releasing hormone agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: luteal phase support with gonadotropin-releasing hormone agonist
Trial: NCT02362945
Drug: Intervention group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl 0.9% solution IV).
Trial: NCT00798317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection placebo.
Trial: NCT01930890
Drug: oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
Trial: NCT04021173
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
Trial: NCT01024491
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active daily treatment with placebo
Trial: NCT00996281
Drug: Azilsartan medoxomil and chlorthalidone
RxNorm normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet.
Trial: NCT01794741
Drug: Dymista Nasal Spray
RxNorm normalized name: Dymista Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04535713
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18 mg/m2 (Maximum Dose: 32 mg) i.v. on Day 1 and Day 8 of Cycle 1+
Trial: NCT00902993
Drug: AZD1446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, oral single and multiple dose
Trial: NCT00902993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03054350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dose
Trial: NCT02351687
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00881153
Drug: Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02088073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)
Trial: NCT02345668
Drug: Treatment as Usual (Pharmacological Treatment)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Pharmacological Treatment provided by a psychiatrist in the mental health unit.
Trial: NCT01468610
Drug: desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50-100 mg daily for 8 weeks
Trial: NCT01023087
Drug: Non-nephrotoxic antibiotics
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be decided by the infectious disease consultant
Trial: NCT00390117
Drug: CDKI AT7519
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
Trial: NCT00016744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo dose will match the oral tablets in arm 1, maintaining the study blind.
Trial: NCT04060381
Drug: Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment/ intervention given according to standard protocols at the Neonatal Intensive Care Unit
Trial: NCT03332719
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00196586
Drug: Interleukin 2
RxNorm normalized name: Recombinant interleukin 2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01497509
Drug: Bolus 10mL 0.25% bupivacaine/ epinephrine 1:600,000;infusion 10mL/hour 0.25% bupivacaine, 2 mcg/mL fentanyl, and epinephrine 1:800,000
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02969590
Drug: Progestin
RxNorm normalized name: Progestin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic progestin to assess effects on cervical mucus.
Trial: NCT02704923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drops characterized by saline administered by sublingual way (2 drops) every 6 hours
Trial: NCT00171925
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance \> 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg\*hr/l).
Trial: NCT01943838
Drug: SAR245408
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet Route of administration: oral
Trial: NCT04381325
Drug: MSB0254 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous infusion with concentration from 4 mg/kg to 16 mg/kg every 2 weeks (Q2W).~An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W).
Trial: NCT03023826
Drug: LY3202626 (R-Fasting)
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03023826
Drug: LY3202626 (T1-Fed)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00182767
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03749096
Drug: Intravenous Immunoglobulins, Human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulins are fractionated blood products made from pooled human plasma.
Trial: NCT03749096
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT01763320
Drug: medical group
RxNorm normalized name: ALCOHOL 266.1615 mL in 354.882 mL TOPICAL GEL [Iconic Medical Group Hand Sanitizer - 12oz 12oz]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter